BioDelivery Sciences International (NASDAQ:BDSI) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Monday. The brokerage presently has a $3.25 price objective on the specialty pharmaceutical company’s stock. Zacks Investment Research‘s price target would indicate a potential upside of 14.04% from the stock’s previous close.

According to Zacks, “BioDelivery secured improved positioning in six new managed care contracts providing preferred access to its key drug, Bunavail. This is expected to boost the drug’s sales and profitability. Meanwhile, launch of its second marketed drug, Belbuca in Canada for severe pain should support sales growth. Appointment of Herm Cukier who has a good track record of bringing growth as its new CEO is expected to bode well for its products. BioDelivery’s shares have outperformed the industry in the past three months. However, given the lackluster performance of Bunavail, BioDelivery decided to reduce spending on the drug. Moreover, the company’s portfolio as well as its pipeline candidates may also face severe competition as it targets a highly genericized and crowded market. Earnings estimates have remained stable ahead of the company’s Q2 earnings release. The company has a mixed record of earnings surprises in recent quarters.”

Several other research analysts have also recently commented on BDSI. HC Wainwright reiterated a “buy” rating and issued a $4.00 price target on shares of BioDelivery Sciences International in a research note on Friday, July 6th. Roth Capital set a $4.00 price target on BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Friday, May 11th. ValuEngine upgraded BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. Finally, Cantor Fitzgerald set a $5.00 price target on BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Monday, May 7th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $4.18.

Shares of BioDelivery Sciences International traded up $0.05, reaching $2.85, during midday trading on Monday, according to Marketbeat.com. 600 shares of the company were exchanged, compared to its average volume of 303,133. The stock has a market cap of $166.18 million, a PE ratio of -7.31 and a beta of 0.48. BioDelivery Sciences International has a 1-year low of $1.70 and a 1-year high of $3.60. The company has a debt-to-equity ratio of 35.82, a current ratio of 1.40 and a quick ratio of 1.13.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings data on Thursday, May 10th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.03. The company had revenue of $11.28 million for the quarter, compared to analysts’ expectations of $10.77 million. BioDelivery Sciences International had a negative return on equity of 388.58% and a negative net margin of 122.75%. research analysts anticipate that BioDelivery Sciences International will post -0.67 earnings per share for the current year.

Several large investors have recently added to or reduced their stakes in the stock. venBio Select Advisor LLC lifted its stake in shares of BioDelivery Sciences International by 120.2% in the first quarter. venBio Select Advisor LLC now owns 5,437,779 shares of the specialty pharmaceutical company’s stock worth $12,235,000 after acquiring an additional 2,968,291 shares in the last quarter. GSA Capital Partners LLP raised its stake in BioDelivery Sciences International by 12.7% during the first quarter. GSA Capital Partners LLP now owns 460,567 shares of the specialty pharmaceutical company’s stock valued at $1,036,000 after buying an additional 51,900 shares in the last quarter. Foresite Capital Management III LLC acquired a new stake in BioDelivery Sciences International during the first quarter valued at approximately $338,000. Knott David M acquired a new stake in BioDelivery Sciences International during the first quarter valued at approximately $270,000. Finally, Millennium Management LLC acquired a new stake in BioDelivery Sciences International during the fourth quarter valued at approximately $310,000. Institutional investors and hedge funds own 46.10% of the company’s stock.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Read More: Understanding Analyst Recommendations

Get a free copy of the Zacks research report on BioDelivery Sciences International (BDSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.